Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination

Purpose: Although the development of immune-based therapies for various cancers including malignant glioma has been heralded with much hope and optimism, objective clinical improvements in most vaccinated cancer patients have not been realized. To broaden the search for vaccine-induced benefits, we examined synergy of vaccines with conventional chemotherapy. Experimental Design: Survival and progression times were analyzed retrospectively in 25 vaccinated (13 with and 12 without subsequent chemotherapy) and 13 nonvaccinated de novo glioblastoma (GBM) patients receiving chemotherapy. Immune responsiveness and T-cell receptor excision circle (TREC) content within CD8+ T cells (CD8+ TRECs) was determined in vaccinated patients. Results: Vaccinated patients receiving subsequent chemotherapy exhibited significantly longer times to tumor recurrence after chemotherapy relative to their own previous recurrence times, as well as significantly longer postchemotherapy recurrence times and survival relative to patients receiving isolated vaccination or chemotherapy. Patients exhibiting objective (>50%) tumor regression, extremely rare in de novo GBM, were also confined to the vaccine + chemotherapy group. Prior tumor behavior, demographic factors, other treatment variables, distribution of vaccine responders, and patients with high CD8+ TRECs all failed to account for these differences in clinical outcome. Within all GBM patients receiving post-vaccine chemotherapy, however, CD8+ TRECs predicted significantly longer chemotherapeutic responses, revealing a strong link between the predominant T-cell effectors in GBM and tumor chemosensitivity. Conclusions: We propose that therapeutic vaccination synergizes with subsequent chemotherapy to elicit tangible clinical benefits for GBM patients.

[1]  K. Black,et al.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. , 2001, Cancer research.

[2]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[3]  F. Davis,et al.  Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. , 2001, Neuro-oncology.

[4]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[5]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.

[6]  R. Koup,et al.  Generation of functional thymocytes in the human adult. , 1999, Immunity.

[7]  F. Marincola,et al.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.

[8]  R. Collins,et al.  Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution , 2000, The Lancet.

[9]  J. Slattery,et al.  Chemotherapy response criteria in malignant glioma , 1997, Neurology.

[10]  R. Clatterbuck,et al.  The Prognostic Value of Tumor Markers in Patients with Glioblastoma Multiforme: Analysis of 32 Patients and Review of the Literature , 2001, Journal of Neuro-Oncology.

[11]  F. Marincola,et al.  Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. , 2000, Journal of the National Cancer Institute.

[12]  F. Marincola,et al.  Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination , 2001, The Journal of Immunology.

[13]  K. Dietzmann,et al.  Sex Differences in Length of Survival with Malignant Astrocytoma, But not with Glioblastoma , 2001, Journal of Neuro-Oncology.

[14]  P. Matzinger.  The JAM test. A simple assay for DNA fragmentation and cell death. , 1991, Journal of immunological methods.

[15]  R. Kaplan.  Supratentorial malignant gliomas: risk patterns and therapy. , 1993, Journal of the National Cancer Institute.

[16]  K. Black,et al.  Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality 1 , 2003, The Journal of Immunology.

[17]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[18]  T. Cloughesy,et al.  Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. , 1999, Journal of neurosurgery.

[19]  E. Perkins,et al.  Long-term remission of malignant brain tumors after intracranial infection: a report of four cases. , 1999, Neurosurgery.

[20]  Louis J. Picker,et al.  Changes in thymic function with age and during the treatment of HIV infection , 1998, Nature.

[21]  J. Maroon,et al.  Value of surgical intervention in the treatment of glioma. , 1995, Stereotactic and functional neurosurgery.

[22]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[24]  J. Bertino,et al.  Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase. , 2002, Molecular cancer therapeutics.

[25]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[26]  Long-term survival in patients with glioblastoma multiforme. , 1993, Neurosurgery.

[27]  B. Bodey,et al.  Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. , 2000, Anticancer research.

[28]  F. Lang,et al.  Current Surgical Management of Glioblastoma , 2003, Cancer journal.

[29]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[30]  Michael S. B. Edwards,et al.  Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. , 1989, Journal of neurosurgery.

[31]  E. Cohen,et al.  Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. , 1997, Neurosurgery.

[32]  P. Warnke,et al.  Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. , 1993, Journal of neurosurgery.

[33]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[34]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[35]  H. Ragde,et al.  Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic disease , 1999, The Prostate.

[36]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.